Want to see NRSN full AI Analyst Report?
Top Page
Neurosense Therapeutics Ltd.
(NASDAQ:NRSN)
Select Model
Select Model
Rating:39Underperform
Price Target:
$2.50
▲(509.76% Upside)
Action:Downgraded
Date:10/20/26
The score is driven primarily by weak financial performance (no revenue, ongoing losses, negative free cash flow, and negative equity), which raises funding and sustainability risk. Technicals further pressure the score as the stock trades far below key moving averages with negative momentum. Valuation contributes only modestly because the negative P/E reflects unprofitability and there is no dividend yield data to offset risk.
Positive Factors
Clinical evidence for PrimeC
Positive Phase 2b results provide clinical support for PrimeC’s multi-pathway approach and may strengthen the case for continued development. Slower functional decline, biomarker shifts and survival findings could improve regulatory and partnering prospects if confirmed in later-stage studies.
Negative Factors
Pre-revenue operating model
The company has no commercial revenue to offset research and development spending, leaving its financial profile dependent on future clinical or regulatory success. Persistent losses of this scale increase the time required to reach self-sustaining operations and heighten execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical evidence for PrimeC
Positive Phase 2b results provide clinical support for PrimeC’s multi-pathway approach and may strengthen the case for continued development. Slower functional decline, biomarker shifts and survival findings could improve regulatory and partnering prospects if confirmed in later-stage studies.
Read all positive factors
Neurosense Therapeutics Ltd. (NRSN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.67M
Dividend YieldN/A
Average Volume (3M)24.76K
Price to Earnings (P/E)―
Beta (1Y)1.05
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-8.91
Shares Outstanding1,896,902
10 Day Avg. Volume27,551
30 Day Avg. Volume24,759
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-12.56
Price to Sales (P/S)0.00
P/FCF Ratio-2.55
Enterprise Value/Market Cap5.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.22
Forecast
1Y Price Target
$78.50Price Target Upside19046.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-5.05
Revenue Forecast (FY)N/A
Neurosense Therapeutics Ltd. Business Overview & Revenue Model
Company Description
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading ...
How the Company Makes Money
As a clinical-stage biotechnology company, NeuroSense Therapeutics does not have publicly available information indicating recurring commercial revenue from approved products. The company’s funding has primarily been associated with typical pre-co...
Neurosense Therapeutics Ltd. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
22
Negative
Cash Flow
15
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -89.00K | 0.00 |
| EBITDA | -11.11M | -9.88M | -9.64M | -12.23M | -2.88M |
| Net Income | -11.13M | -10.21M | -10.11M | -12.34M | -4.04M |
Balance Sheet | |||||
| Total Assets | 1.03M | 4.58M | 3.19M | 7.71M | 11.43M |
| Cash, Cash Equivalents and Short-Term Investments | 166.00K | 3.38M | 2.64M | 7.09M | 11.06M |
| Total Debt | 170.00K | 73.00K | 142.00K | 211.00K | 0.00 |
| Total Liabilities | 2.59M | 1.99M | 4.94M | 2.09M | 2.42M |
| Stockholders Equity | -1.56M | 2.58M | -1.76M | 5.62M | 9.01M |
Cash Flow | |||||
| Free Cash Flow | -7.68M | -10.14M | -8.38M | -7.66M | -1.56M |
| Operating Cash Flow | -7.67M | -10.13M | -8.35M | -7.59M | -1.54M |
| Investing Cash Flow | -8.00K | 1.00K | 3.47M | -3.54M | -17.00K |
| Financing Cash Flow | 4.43M | 10.91M | 3.98M | 3.69M | 11.90M |
Neurosense Therapeutics Ltd. Technical Analysis
Negative
0.41
Price Trends
6.02
Negative
9.61
Negative
13.33
Negative
Market Momentum
-1.12
Negative
24.35
Positive
19.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRSN, the sentiment is Negative. The current price of 0.41 is below the 20-day moving average (MA) of 3.51, below the 50-day MA of 6.02, and below the 200-day MA of 13.33, indicating a bearish trend. The MACD of -1.12 indicates Negative momentum. The RSI at 24.35 is Positive, neither overbought nor oversold. The STOCH value of 19.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NRSN.
Neurosense Therapeutics Ltd. Risk Analysis
Neurosense Therapeutics Ltd. disclosed 69 risk factors in its most recent earnings report. Neurosense Therapeutics Ltd. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
If we fail to maintain compliance with Nasdaq's continued listing requirements, our shares may be delisted from the Nasdaq Capital Market. Q4, 2023
2.
If a United States person is treated as owning at least 10% of our ordinary shares, such holder may be subject to adverse U.S. federal income tax consequences. Q4, 2023
3.
Environmental, social and corporate governance, or ESG, issues, including those related to climate change and sustainability, may have an adverse effect on our business, financial condition and results of operations and damage our reputation. Q4, 2023
Neurosense Therapeutics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $92.93M | -9.61 | -173.28% | ― | 65.22% | 24.92% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $6.94M | -0.39 | -215.58% | ― | -86.76% | 16.63% | |
42 Neutral | $64.37M | -1.15 | -61.55% | ― | ― | -59.74% | |
41 Neutral | $6.87M | -0.80 | -237.91% | ― | ― | 23.05% | |
39 Underperform | $4.67M | -0.35 | 723.04% | ― | ― | ― |
* Healthcare Sector Average
NRSN
Neurosense Therapeutics Ltd.
2.33
-20.47
-89.78%
TENX
Tenax Therapeutics
1.64
-5.86
-78.13%
CLGN
Collplant Holdings
3.75
-19.60
-83.94%
XCUR
Exicure
1.09
-3.59
-76.71%
NRXS
NeurAxis, Inc.
7.25
4.14
133.12%
Neurosense Therapeutics Ltd. Corporate Events
NeuroSense Files U.S. Patent to Extend PrimeC into Traumatic Brain Injury
Oct 19, 2026
On October 19, 2026, NeuroSense Therapeutics announced it had filed a U.S. patent application covering the use of PrimeC’s combination of ciprofloxacin and celecoxib to treat traumatic brain injury and related central nervous system injuries...
NeuroSense Wins Nasdaq Hearing Date as PrimeC Nears Key Regulatory and Funding Milestones
Oct 13, 2026
NeuroSense Therapeutics Ltd., a late-stage clinical biotech focused on ALS and Alzheimer’s disease, is advancing PrimeC, its oral extended-release combination of ciprofloxacin and celecoxib that targets multiple neurodegenerative pathways, i...
NeuroSense Regains Nasdaq Bid Price Compliance, Appeals Market Value Delisting Notice
Oct 2, 2026
NeuroSense Therapeutics, a Nasdaq-listed biotechnology developer of treatments for neurodegenerative diseases, reported new listing compliance developments that highlight both regulatory risk and its continued clinical ambitions. The company, whic...
NeuroSense Advances PrimeC ALS Program and Cuts Costs in H1 2026
Sep 25, 2026
In the first half of 2026, NeuroSense reported clinical and regulatory progress for PrimeC in ALS, highlighted by publication of Phase 2b PARADIGM trial results in JAMA Neurology in March and long-term survival data in February showing a 65% reduc...
NeuroSense Therapeutics to Enact 1-for-20 Reverse Share Split on Nasdaq
Sep 9, 2026
On September 9, 2026, NeuroSense Therapeutics announced it would implement a 1-for-20 reverse share split of its Nasdaq-listed ordinary shares. The consolidation will reduce the number of issued and outstanding shares from 37,938,036 to approximat...
NeuroSense Shareholders Approve Flexible Reverse Share Split Authorization
Aug 27, 2026
On August 26, 2026, NeuroSense Therapeutics Ltd. held a special meeting of shareholders where investors approved authorizing the board to execute one or more reverse share splits of the company’s ordinary shares. The approved aggregate ratio...
NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts
Aug 13, 2026
NeuroSense Therapeutics has released a CEO letter dated August 13, 2026, outlining preparations for PARAGON, its pivotal Phase 3 trial of PrimeC in ALS, following U.S. FDA clearance to enroll about 300 participants primarily in the United States. ...
NeuroSense Advances PrimeC Toward December 2026 Health Canada Filing After Completing Pre-NDS Process
Aug 6, 2026
On August 6, 2026, NeuroSense Therapeutics reported that it has completed the Pre-NDS process with Health Canada for PrimeC, its lead ALS candidate, and is working toward filing a New Drug Submission in early December 2026. Meeting minutes from th...
NeuroSense Updates Capital on Demand Program After New F-3 Becomes Effective
Jul 31, 2026
On July 31, 2026, NeuroSense Therapeutics Ltd. amended its Capital on Demand sales agreement with JonesTrading to align it with a newly effective Form F-3 shelf registration declared effective the same day by the U.S. Securities and Exchange Commi...
NeuroSense Therapeutics Calls August 26 Shareholder Vote on Wide-Range Reverse Share Split
Jul 31, 2026
NeuroSense Therapeutics Ltd. has called a Special Meeting of Shareholders for August 26, 2026, at its Ra’anana, Israel headquarters to seek approval for a significant change to its capital structure. Shareholders of record as of July 31, 202...
NeuroSense Moves PrimeC Toward Health Canada Drug Submission for ALS
Jul 22, 2026
NeuroSense Therapeutics, a late-stage clinical biotech developer of neurodegenerative disease treatments, is advancing its lead candidate PrimeC, a multi-pathway oral combination therapy targeting mechanisms such as neuroinflammation, oxidative st...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.